Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)
Oxemia TM (Desidustat) is a breakthrough treatment for Anemia associated with Chronic Kidney Disease (CKD) in ...
Read moreOxemia TM (Desidustat) is a breakthrough treatment for Anemia associated with Chronic Kidney Disease (CKD) in ...
Read moreThe Zydus group announced its new brand identity with the listed entity of the group Cadila ...
Read moreZydus has received final approval from the USFDA to market Dapagliflozin Tablets in the strengths of ...
Read moreZydus’ U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received final approval from the USFDA to market ...
Read moreZydus Cadila has received tentative approval from the USFDA to market Osimertinib Tablets in the strengths ...
Read moreZydus Cadila has received final approval from the USFDA to market Fluphenazine Hydrochloride Tablets in the ...
Read moreZydus seeks DCGI approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID ...
Read moreZydus and TLC, a specialty pharmaceutical company in Taiwan, today announced the signing of a license ...
Read moreThe therapy will be priced at nearly 80% less than the currently available option in the ...
Read moreSharvil Patel is the joint Managing Director of Zydus Cadila Healthcare Limited which is India’s fourth-largest ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.